|Articles|July 1, 2000

Overactive Bladder: Examining the Burden of Disease
Volume 6
Issue 11 Suppl

Overactive Bladder: Special Considerations in the Geriatric Population

Author(s)Joseph G. Ouslander, MD, Ya-chen Tina Shih, PhD, James Malone-Lee, MD

Download PDF: Overactive Bladder: Special Considerations in the Geriatric Population

Articles in this issue

about 26 years ago

Article

Discussion

about 26 years ago

Article

Bibliography

about 26 years ago

Article

Participating Faculty

about 26 years ago

Article

Introduction: Overactive Bladder - Defining the Disease

about 26 years ago

Article

The Prevalence of Overactive Bladder

about 26 years ago

Article

Comorbidities Associated with Overactive Bladder

about 26 years ago

Article

Overactive Bladder Significantly Affects Overall Quality of Life

about 26 years ago

Article

Economic Considerations in Overactive Bladder

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Overactive Bladder: Special Considerations in the Geriatric Population

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

AI Phenotyping Links Cardiovascular, Kidney Disease to Rapid MASH Progression, Higher Costs

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

Clinical Trials Leave Many ALL Patients Behind: Emily K. Curran, MD